ExiTron™ ultra 18000 is a nanoparticulate CT contrast agent developed for preclinical CT angiography applications requiring very high X ray attenuation. It is based on a post transition metal formulation designed to provide strong and stable vascular contrast in small animal models. The combination of pronounced contrast enhancement and extended blood circulation time enables detailed assessment of vascular structures across a wide acquisition window. Ordering through an authorized distributor ensures reliable supply, compliant shipping, and access to technical expertise for advanced angiographic studies.
Left: Axial and sagittal CT images before (upper row), immediately after (middle row) and 5 hours post (lower row) injection of ExiTron ultra 18000 showing the agent’s exceptional vascular contrast.
Right: Timecourse of the signal enhancement in blood as well as in liver of mice after injection of ExiTron ultra 18000.
High resolution CT angiography places stringent demands on contrast intensity and temporal stability. ExiTron™ ultra 18000 addresses these requirements by providing substantially elevated attenuation within the blood pool while maintaining prolonged intravascular residence. This imaging profile supports visualization of fine vascular structures and facilitates assessment of regions with altered vascular permeability that may be associated with pathological processes.
Following intravenous administration, ExiTron™ ultra 18000 produces strong and sustained enhancement of the vascular system. The high attenuation level enables clear delineation of vessels over time, supporting imaging immediately after injection as well as at delayed time points. Signal enhancement profiles in blood and liver allow characterization of contrast distribution and clearance dynamics, contributing to reproducible angiographic imaging outcomes.
ExiTron™ ultra 18000 is suitable for detailed visualization of the vascular system in small animal models. It supports detection of regions with increased vascular permeability and is applicable to advanced CT modalities such as spectral and photon counting CT. The broad imaging time window allows flexibility in study design and accommodates complex acquisition protocols.
ExiTron™ ultra 18000 consists of nanoparticles engineered for vascular imaging stability and high contrast performance. The mean hydrodynamic diameter is approximately 300 nanometers. Undiluted X ray attenuation reaches approximately 18,000 Hounsfield units, providing exceptionally strong contrast for preclinical CT angiography systems.
CT angiography studies demonstrate marked vascular enhancement using ExiTron™ ultra 18000 across multiple imaging time points. Comparative imaging before and after administration highlights the degree of contrast enhancement achievable, while time course analyses illustrate sustained blood pool signal suitable for longitudinal and advanced CT applications.
The use of ExiTron™ ultra 18000 and related formulations has been described in peer reviewed research focusing on dual contrast and photon counting CT methodologies, including studies evaluating novel high attenuation contrast agents for preclinical imaging.
ExiTron™ ultra 18000 is available in packaging options appropriate for pilot experiments or extended research programs, including formats containing one set of five injections or five sets of five injections. Ordering through an authorized distributor provides access to local support, institutional purchasing processes, and customized quotations.
Authorized distributor of Viscover products by Nanopet Pharma GmbH. This page presents original distributor specific content intended to support preclinical CT angiography research.
Price range: USD $719 through USD $3,329
